Lilly's Foundayo Phase 3 Diabetes Trial Shows 57% Lower All-Cause Death, FDA Submission Planned
LLY sits 46% above its 52-week low of $623.78.
Summary
Eli Lilly announced positive results from its longest Phase 3 study (Achieve-4) of Foundayo for Type 2 Diabetes, affirming its cardiovascular and overall safety profile. The trial demonstrated consistent improvements in cardiometabolic health and, notably, a 57% lower risk of all-cause death for Foundayo versus insulin glargine in a pre-planned analysis. This follows recent FDA approval and launch of Foundayo for obesity, indicating a significant expansion of the drug's potential market. The strong safety and efficacy data, particularly the substantial reduction in all-cause mortality, positions Foundayo as a highly competitive treatment for Type 2 Diabetes. Lilly plans to submit Foundayo for the treatment of Type 2 Diabetes to the U.S. FDA by the end of the second quarter, which could substantially increase the drug's peak sales potential.
At the time of this announcement, LLY was trading at $912.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $855.1B. The 52-week trading range was $623.78 to $1,133.95. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.